Literature DB >> 23681867

Recent advancements in the drug treatment of endocrine diseases.

Amir H Sam1, Karim Meeran.   

Abstract

Recent years have seen several advances in the management of endocrine diseases. These include novel drugs developed as a consequence of better understanding of the pathophysiology of endocrine conditions, as well as improved delivery methods for existing drugs. In this article, we summarise recent studies evaluating several drugs used in the treatment of endocrine disorders.

Entities:  

Keywords:  endocrine diseases; pharmacotherapy

Mesh：

Year:  2013        PMID： 23681867      PMCID： PMC4952635          DOI： 10.7861/clinmedicine.13-2-170

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


  54 in total

1.  The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.

Authors:  Dolores M Shoback; John P Bilezikian; Stewart A Turner; Laura C McCary; Matthew D Guo; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

2.  Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.

Authors:  George J Kahaly; Susanne Pitz; Gerhard Hommel; Manuela Dittmar
Journal:  J Clin Endocrinol Metab       Date:  2005-07-05       Impact factor: 5.958

3.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

Authors:  P J Trainer; W M Drake; L Katznelson; P U Freda; V Herman-Bonert; A J van der Lely; E V Dimaraki; P M Stewart; K E Friend; M L Vance; G M Besser; J A Scarlett; M O Thorner; C Parkinson; A Klibanski; J S Powell; A L Barkan; M C Sheppard; M Malsonado; D R Rose; D R Clemmons; G Johannsson; B A Bengtsson; S Stavrou; D L Kleinberg; D M Cook; L S Phillips; M Bidlingmaier; C J Strasburger; S Hackett; K Zib; W F Bennett; R J Davis
Journal:  N Engl J Med       Date:  2000-04-20       Impact factor: 91.245

4.  Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.

Authors:  J Feenstra; W W de Herder; S M T H ten Have; A W van den Beld; R A Feelders; J A M J L Janssen; A J van der Lely
Journal:  Lancet       Date:  2005 May 7-13       Impact factor: 79.321

5.  A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Authors:  Shlomo Melmed; Richard Sternberg; David Cook; Anne Klibanski; Philippe Chanson; Vivien Bonert; Mary Lee Vance; David Rhew; David Kleinberg; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2005-04-12       Impact factor: 5.958

6.  Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.

Authors:  Munro Peacock; John P Bilezikian; Preston S Klassen; Matthew D Guo; Stewart A Turner; Dolores Shoback
Journal:  J Clin Endocrinol Metab       Date:  2004-11-02       Impact factor: 5.958

7.  Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.

Authors:  Sigrid Jehle; Carlos M Reyes; Robert E Sundeen; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2004-12-07       Impact factor: 5.958

8.  Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas.

Authors:  M Losa; E Ciccarelli; P Mortini; R Barzaghi; D Gaia; G Faccani; M Papotti; F Mangili; M R Terreni; F Camanni; M Giovanelli
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

9.  Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency.

Authors:  Peak M Mah; Richard C Jenkins; Amin Rostami-Hodjegan; John Newell-Price; Anita Doane; Victoria Ibbotson; Geoffrey T Tucker; Richard J Ross
Journal:  Clin Endocrinol (Oxf)       Date:  2004-09       Impact factor: 3.478

10.  Factors influencing mortality in acromegaly.

Authors:  Ian M Holdaway; Raja C Rajasoorya; Greg D Gamble
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.